Psychedelic Medicine Company Approved To Study Sublingual Psilocybin For Major Depressive Disorder

United States News News

Psychedelic Medicine Company Approved To Study Sublingual Psilocybin For Major Depressive Disorder
United States Latest News,United States Headlines
  • 📰 Forbes
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 53%

A psychedelic medicine company will launch a phase two clinical trial on its sublingual formulation of psilocybin, the psychedelic compound found in “magic mushrooms”, for patients with Major Depressive Disorder later this year

data from its phase three clinical trial with MDMA-assisted therapy for post-traumatic stress disorder, showing that 67% of participants who received three treatments no longer qualified for a PTSD diagnosis and 88% experienced a clinically meaningful reduction in symptoms. Other companies like MindMed, which is studying LSD for anxiety and a modified version of ibogaine to treat opioid-use disorder, have also listed on Nasdaq.

Cybin’s phase two study will be conducted in two parts at Jamaica’s University of West Indies Hospital. The first part of the clinical trial will consist of a Phase IIa study of 40 patients to identify the equivalent dose of Cybin’s sublingual psilocybin formulation compared with a 25 mg pill of psilocybin. Cybin’s sublingual film is designed for rapid absorption, a faster onset, and a shorter duration.

Cybin is starting with psilocybin, but the company is developing novel molecules based on other psychedelic compounds. The company has filed 12 provisional patent applications for novel psychedelic compounds.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Forbes /  🏆 394. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Psychedelic Medicine Company Approved To Study Sublingual Psilocybin For Major Depressive DisorderPsychedelic Medicine Company Approved To Study Sublingual Psilocybin For Major Depressive DisorderA psychedelic medicine company will launch a phase two clinical trial on its sublingual formulation of psilocybin, the psychedelic compound found in “magic mushrooms”, for patients with Major Depressive Disorder later this year
Read more »

How to Recognize Catatonia in Major Depressive DisorderHow to Recognize Catatonia in Major Depressive DisorderRecognizing when someone you love is getting stuck or frozen in a catatonic state could help save them from harm. Here are some signs to watch out for, writes Newtherapisthub
Read more »

7 Major Types of Anxiety Disorders—And How to Identify Them7 Major Types of Anxiety Disorders—And How to Identify ThemAnd what you can do about it.
Read more »

Warner Music Becomes Twitch's First Major-Label PartnerA new deal will bring WMG artist channels, original music programming and more to the livestreaming platform.
Read more »

She’s (Finally) the Boss: Women Are Rising to the Top of Major-Label A&R DepartmentsShe’s (Finally) the Boss: Women Are Rising to the Top of Major-Label A&R DepartmentsRani Hancock, the recently appointed executive vice president and head of Columbia Records’ A&R department, took a bold and uncommon course into the music industry — uncommon for a woman, anywa…
Read more »



Render Time: 2025-04-09 22:03:47